The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,029
Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics
Shen, J., Zhang, W., Qi, R., Mao, Z., & Shen, H. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00479f · Cited by 149
Self-citationGraván, P., Aguilera-Garrido, A., Marchal, J. A., Navarro-Marchal, S. A., & Galisteo-González, F. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.102871 · Cited by 157
“Nanosystems can overcome biological barriers and control the release of drugs to target sites, enabling the use of lower doses while decreasing the side effects and increasing the treatment efficiency [6,7].”
Liu, Y., Yang, F., Yuan, C., Li, M., Wang, T., Chen, B., Jin, J., Zhao, P., Tong, J., Luo, S., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06815 · Cited by 145
Zhou, X. W., Zhang, X., Han, S., Dou, Y., Liu, M., Zhang, L., Guo, J., Shi, Q., Gong, G., Wang, R., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04523 · Cited by 149
A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J., Nizzero, S., Liu, H., Li, F., Zhang, G., Li, Z., Shen, H., Blanco, E., & Mauro Ferrari, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-14221-2 · Cited by 150
Self-citationChen, L., Zhang, S., Duan, Y., Song, X., Chang, M., Feng, W., & Chen, Y. (2024) · Chemical Society Reviews · doi:10.1039/d1cs01022k · Cited by 150
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
Li, M., Zhang, W., Wang, B., Gao, Y., Song, Z., & Zheng, Q. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s115727 · Cited by 148
“The drug delivery system is eliminated by liver, kidney, and reticuloendothelial system (RES), which is based on their physicochemical properties.(29,30) Kidneys filter various metabolites and wastes from the blood into urine through the glomerulus, the pores of which are ~10 nm.”
BackgroundDesign and Development of Biomimetic Nanovesicles Using a Microfluidic Approach
Molinaro, R., Evangelopoulos, M., Hoffman, J., Corbo, C., Taraballi, F., Martinez, J. O., Hartman, K. A., Cosco, D., Costa, G., Romeo, I., et al. (2018) · Advances in Materials · doi:10.1002/adma.201702749 · Cited by 126
Im, S., Lee, J., Park, D., Park, A., Kim, Y., & Kim, W. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b07045 · Cited by 145
Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy
Thomas, R. G., Surendran, S. P., & Jeong, Y. Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.610533 · Cited by 154
“The capability of nanoparticles to accumulate at the tumor site through the effect of EPR is determined by the shape, size, and surface chemistry of the nanoparticles (Blanco et al., 2015).”
BackgroundFunctional supramolecular systems: design and applications
Antipin, I. S., Alfimov, M. V., Arslanov, V. V., Бурилов, В. А., Vatsadze, S. Z., Voloshin, Y. Z., Volcho, K. P., Gorbatchuk, V. V., Gorbunova, Y. G., Gromov, S. P., et al. (2021) · Russian Chemical Reviews · doi:10.1070/rcr5011 · Cited by 144
Bio-acceptable 0D and 1D ZnO nanostructures for cancer diagnostics and treatment
Ortiz-Casas, B., Galdámez‐Martínez, A., Gutiérrez-Flores, J., Ibañez, A. B., Panda, P. K., Santana, G., de la Vega, H. A., Suar, M., Gutiérrez-Rodelo, C., Kaushik, A. K., et al. (2021) · Materials Today · doi:10.1016/j.mattod.2021.07.025 · Cited by 147
Li, M., Jin, X., Liu, T., Fan, F., Gao, F., Chai, S., & Yang, L. (2022) · Nature Communications · doi:10.1038/s41467-022-31882-4 · Cited by 150
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents
Wang, F., Li, C., Cheng, J., & Yuan, Z. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13121182 · Cited by 145
Deep-Tissue Photothermal Therapy Using Laser Illumination at NIR-IIa Window
Wu, X., Suo, Y., Shi, H., Liu, R., Wu, F., Wang, T., Ma, L., Liu, H., & Cheng, Z. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-0378-6 · Cited by 145
Ben‐Akiva, E., Karlsson, J. E., Hemmati, S., Yu, H., Tzeng, S. Y., Pardoll, D. M., & Green, J. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301606120 · Cited by 145
“Previous electro-statically formed NP formulations composed of cationic polymeric nanocarriers have had limited success following systemic administration mainly due to insufficient stability in the presence of anionic serum proteins that readily dissociate the formulations (37, 38).”
BackgroundZhao, T., Wang, P., Li, Q., Al-Khalaf, A. A., Hozzein, W. N., Zhang, F., Li, X., & Zhao, D. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711354 · Cited by 142
Smart Targeting To Improve Cancer Therapeutics
Morales‐Cruz, M., Delgado, Y., Castillo, B., Figueroa, C. M., Molina, A., Torres, A., Milián, M., & Griebenow, K. H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s219489 · Cited by 146
“be increased by vascular endothelial growth factor (VEGF) and nitric oxide in the endothelia.(13,35,36) In con-”
BackgroundA pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases
Zhang, R., Liu, R., Liu, C., Pan, L., Qi, Y., Cheng, J., Guo, J., Jia, Y., Ding, J., Zhang, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119605 · Cited by 142
Chen, Y., Li, Z., Pan, P., Hu, J., Cheng, S., & Zhang, X. (2020) · Advanced Materials · doi:10.1002/adma.202001452 · Cited by 140
Nanomedicine progress in thrombolytic therapy
Zenych, A., Fournier, L., & Chauvierre, C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120297 · Cited by 149
Exosome-mediated delivery of RNA and DNA for gene therapy
Munagala, R., Aqil, F., Jeyabalan, J., Kandimalla, R., Wallen, M., Tyagi, N., Wilcher, S. A., Yan, J., Schultz, D. J., Spencer, W. A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.011 · Cited by 148
Recent Progress and Trends in X-ray-Induced Photodynamic Therapy with Low Radiation Doses
He, L., Yu, X., & Li, W. (2022) · ACS Nano · doi:10.1021/acsnano.2c07286 · Cited by 145
Journal of Global Trends in Pharmaceutical Sciences
Rao, A., Korim, R., Reddy, D. S., & Mujavar, E. (2014) · Cited by 142
Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation
Munoz, L. E., Bilyy, R. O., Biermann, M. H. C., Kienhöfer, D., Maueröder, C., Hahn, J., Brauner, J., Weidner, D., Chen, J., Scharin-Mehlmann, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602230113 · Cited by 143
“(15) emphasized the importance of these barriers for exploiting the clinical potential of NP-based drug delivery (15).”
BackgroundMa, N., Jiang, Y., Zhang, X., Wu, H., Myers, J. N., Liu, P., Jin, H., Gu, N., He, N., Wu, F., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10132 · Cited by 141
Tefas, L. R., Sylvester, B., Tomuță, I., Sesărman, A., Licărete, E., Banciu, M., & Porfire, A. S. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s129008 · Cited by 141
“Also, nanoparticles with a size of 100–200 nm have been shown to be able to extravasate through the fenestrations of the endothelial lining of blood vessels and leak into tumors to a greater extent than in normal tissues due to the enhanced permeation and retention effect.(41) However, by ensuring a small size for the…”
BackgroundMicrofluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles
Li, X., & Jiang, X. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.12.015 · Cited by 145
Meng, Y., Zhang, Z., Yin, H., & Ma, T. (2017) · Micron · doi:10.1016/j.micron.2017.12.002 · Cited by 141
Rathore, B., Sunwoo, K., Jangili, P., Kim, J., Kim, J. H., Huang, M., Xiong, J., Sharma, A. K., Yang, Z., Qu, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.05.002 · Cited by 141
Matsumoto, A., Takahashi, Y., Chang, H., Wu, Y.-W., Yamamoto, A., Ishihama, Y., & Takakura, Y. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1696517 · Cited by 146
“For the isolation step, physiochemically intact sEVs are desirable because this property is a critical determinant of nanoparticle clearance from blood circulation [5].”
BackgroundStimulus-responsive self-assembled prodrugs in cancer therapy
Dong, X., Brahma, R. K., Fang, C., & Yao, S. Q. (2022) · Chemical Science · doi:10.1039/d2sc01003h · Cited by 141
Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures
Zhu, M., Zhuang, J., Li, Z., Liu, Q., Zhao, R., Gao, Z., Midgley, A. C., Qi, T., Tian, J., Zhang, Z., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01323-4 · Cited by 140
Sheng, J., Wang, L., Han, Y., Chen, W., Liu, H., Zhang, M., Deng, L., & Liu, Y. (2017) · Small · doi:10.1002/smll.201702529 · Cited by 140
Abello, J., Nguyen, T. D. T., Marasini, R., Aryal, S., & Weiss, M. L. (2019) · Theranostics · doi:10.7150/thno.30030 · Cited by 142
“Nevertheless, these approaches have limitations such as bio-incompatibility [43], development of allergic reactions [44] and lack of target specificity [45, 46].”
BackgroundFusco, L., Gazzi, A., Peng, G., Shin, Y., Vranic, S., Bedognetti, D., Vitale, F., Yılmazer, A., Feng, X., Fadeel, B., et al. (2020) · Theranostics · doi:10.7150/thno.40068 · Cited by 140
“Indeed, the latter is characterized by slower blood flow and the presence of holes (fenestration) that should be taken into consideration in 2D design and production to predict the possible extravasation to reach the tumor region [302].”
BackgroundAbdel-Mageed, H. M., AbuelEzz, N. Z., Radwan, R. A., & Mohamed, S. A. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1942275 · Cited by 145
“Measurements of size and zeta potential are routinely performed on the same instrument such as dynamic light scattering (DLS) and laser Doppler electrophoresis (LDE), but require multiple experiments, and are challenged by polydisperse samples (Blanco et al. 2015).”
BackgroundBao, Y., Yin, M., Hu, X., Zhuang, X., Sun, Y., Guo, Y., Tan, S., & Zhang, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.003 · Cited by 139
“In cancer therapy, the therapeutic efficacy of nanomedicine depends not only on nanoparticles localization at the tumor tissue but also on the amount of drug that can take effect [18].”
BackgroundCong, Z., Zhang, L., Ma, S.-Q., Lam, K. S., Yang, F.-F., & Liao, Y. (2020) · ACS Nano · doi:10.1021/acsnano.9b08434 · Cited by 140
Kooijmans, S. A. A., de Jong, O. G., & Schiffelers, R. M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.017 · Cited by 147
Wang, R., Yin, C., Liu, C., Sun, Y., Xiao, P., Li, J., Yang, S., Wu, W., & Jiang, X. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09741 · Cited by 140
Chen, J., Ding, J., Xu, W., Sun, T., Xiao, H., Zhuang, X., & Chen, X. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02129 · Cited by 138
Haute, D. V., & Berlin, J. M. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0057 · Cited by 143
Dual-targeted nanomedicines for enhanced tumor treatment
Zhu, Y., Feijén, J., & Zhong, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2017.12.007 · Cited by 139
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 146
“reviewed biological barriers to nanoparticle delivery, highlighting the influence of the physicochemical and geometric properties of nanoparticles (Blanco et al., 2015).”
BackgroundTumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity
Ryu, J. H., Yoon, H. Y., Sun, I., Kwon, I. C., & Kim, K. (2020) · Advanced Materials · doi:10.1002/adma.202002197 · Cited by 141
Cancer Therapy by Silver Nanoparticles: Fiction or Reality?
Kovács, D., Igaz, N., Gopisetty, M. K., & Kiricsi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020839 · Cited by 141
Beyond the EPR effect: Intravital microscopy analysis of nanoparticle drug delivery to tumors
Belyaev, I. B., Griaznova, O. Y., Yaremenko, A. V., Deyev, S. M., & Zelepukin, I. V. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115550 · Cited by 145
“In addition, NPs should be larger than 6 nm to avoid renal clearance [47] and preferably smaller than 200 nm to reduce uptake by tissue-resident macrophages [48,49].”
Molecular engineering solutions for therapeutic peptide delivery
Acar, H., Ting, J., Srivastava, S., LaBelle, J. L., & Tirrell, M. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00536a · Cited by 139
Liu, Y., Wang, Z., Liu, Y., Zhu, G., Jacobson, O., Fu, X., Bai, R., Lin, X., Lu, N., Yang, X., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b05908 · Cited by 137
Gold nanoclusters for biomedical applications: toward in vivo studies
Porret, E., Guével, X. L., & Coll, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02767j · Cited by 141
Layered Double Hydroxides: Recent Progress and Promising Perspectives Toward Biomedical Applications
Li, L., Soyhan, I., Warszawik, E. M., & van Rijn, P. (2024) · Advanced Science · doi:10.1002/advs.202306035 · Cited by 143
Nanotechnology: from In Vivo Imaging System to Controlled Drug Delivery
Mir, M., Ishtiaq, S., Rabia, S., Khatoon, M., Zeb, A., Khan, G. M., Rehman, A. U., & Din, F. U. (2017) · Nanoscale Research Letters · doi:10.1186/s11671-017-2249-8 · Cited by 140
Multiplexed mRNA Sensing and Combinatorial-Targeted Drug Delivery Using DNA-Gold Nanoparticle Dimers
Kyriazi, M. E., Giust, D., El-Sagheer, A. H., Lackie, P. M., Muskens, O. L., Brown, T. P., & Kanaras, A. G. (2018) · ACS Nano · doi:10.1021/acsnano.7b08620 · Cited by 136
Simon, J., Muller, L. K., Kokkinopoulou, M., Lieberwirth, I., Morsbach, S., Landfester, K., & Mailänder, V. (2018) · Nanoscale · doi:10.1039/c8nr03331e · Cited by 135
Chen, Q., Luo, Y., Du, W., Liu, Z., Zhang, S., Yang, J., Yao, H., Liu, T., Ma, M., & Chen, H. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b02905 · Cited by 135
Fusion dynamics of cubosome nanocarriers with model cell membranes
Dyett, B., Yu, H., Strachan, J. B., Drummond, C. J., & Conn, C. E. (2019) · Nature Communications · doi:10.1038/s41467-019-12508-8 · Cited by 135
Li, B., Hao, G., Sun, B. F., Gu, Z., & Xu, Z. P. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909745 · Cited by 136
Sushnitha, M., Evangelopoulos, M., Tasciotti, E., & Taraballi, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00627 · Cited by 137
“mononuclear phagocyte system (MPS), and natural clearance by filtering organs (Blanco et al., 2015).”
BackgroundNon-spherical micro- and nanoparticles for drug delivery: Progress over 15 years
Kapate, N., Clegg, J. R., & Mitragotri, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.017 · Cited by 139
Gao, X., Cui, R., Ji, G., & Liu, Z. (2018) · Nanoscale · doi:10.1039/c7nr08892b · Cited by 135
Antimicrobial activities of green synthesized gums-stabilized nanoparticles loaded with flavonoids
Anwar, A., Masri, A., Rao, K., Rajendran, K., Khan, N. A., Shah, M. R., & Siddiqui, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-39528-0 · Cited by 135
Recent advances in drug delivery systems for enhancing drug penetration into tumors
He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831106 · Cited by 143
Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
Frickenstein, A. N., Hagood, J. M., Britten, C. N., Abbott, B. S., McNally, M. W., Vopat, C. A., Patterson, E. G., MacCuaig, W. M., Jain, A., Walters, K. B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040570 · Cited by 142
“NPs with negative charges are less likely overall to interact with or be engulfed by nonphagocytic cells, thus, prolonging the NP circulation time [73,74].”
BackgroundApplication of nanotechnology in medical diagnosis and imaging
Singh, A., & Amiji, M. M. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.12.011 · Cited by 135
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 146
Mehraji, S., & DeVoe, D. L. (2024) · Lab on a Chip · doi:10.1039/d3lc00821e · Cited by 144
Technology Roadmap of Micro/Nanorobots
Ju, X., Chen, C., Oral, Ç. M., Sevim, S., Golestanian, R., Sun, M., Bouzari, N., Lin, X., Urso, M., Nam, J. S., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03911 · Cited by 143
Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
Zhao, Y., Fay, F., Hak, S., Perez‐Aguilar, J. M., Sánchez-Gaytán, B. L., Brandon, G., Duivenvoorden, R., Davies, C. D. L., Bjørkøy, A., Weinstein, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms11221 · Cited by 136
GraftFast Surface Engineering to Improve MOF Nanoparticles Furtiveness
Giménez‐Marqués, M., Bellido, E., Berthelot, T., Simón‐Yarza, T., Hidalgo, T., Simón‐Vázquez, R., González‐Fernández, Á., Avila, J., Asensio, M. C., Gref, R., et al. (2018) · Small · doi:10.1002/smll.201801900 · Cited by 135
Dai, L., Li, X., Duan, X., Li, M., Niu, P., Xu, H., Cai, K., & Yang, H. (2018) · Advanced Science · doi:10.1002/advs.201801807 · Cited by 134
Nanomedicine and drug delivery systems in cancer and regenerative medicine
Garbayo, E., Pascual‐Gil, S., Rodríguez‐Nogales, C., Saludas, L., de Mendoza, A. E., & Blanco‐Prieto, M. J. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1637 · Cited by 140
Obst, K., Yealland, G., Balzus, B., Miceli, E., Dimde, M., Weise, C., Eravci, M., Bodmeier, R. A., Haag, R., Calderón, M., et al. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00158 · Cited by 137
Wen, Y. F., Zhang, W., Gong, N., Wang, Y., Guo, H., Guo, W., Wang, P. C., & Liang, X. (2017) · Nanoscale · doi:10.1039/c7nr03129g · Cited by 133
Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics
Cassano, D., Pocoví‐Martínez, S., & Voliani, V. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00664 · Cited by 134
Yan, J., He, W., Yan, S., Niu, F., Liu, T., Ma, B., Shao, Y., Yan, Y., Yang, G., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00081 · Cited by 133
Zhang, X., Xu, X., Li, Y., Hu, C., Zhang, Z., & Gu, Z. (2018) · Advanced Materials · doi:10.1002/adma.201707240 · Cited by 133
Tsiaoussis, J., Antoniou, M. N., Koliarakis, I., Mesnage, R., Vardavas, C. I., Izotov, B. N., Psaroulaki, A., & Tsatsakis, A. M. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.04.014 · Cited by 139
“hyper-selective accumulation of chemotherapeutic agents at tumor sites (Blanco et al., 2015; 888 Wilhelm et al., 2016).”
BackgroundFrancia, V., Montizaan, D., & Salvati, A. L. (2020) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.11.25 · Cited by 142
Surface modified cellulose nanomaterials: a source of non-spherical nanoparticles for drug delivery
Khine, Y. Y., & Stenzel, M. H. (2020) · Materials Horizons · doi:10.1039/c9mh01727e · Cited by 132
Delivery Systems for Nucleic Acids and Proteins: Barriers, Cell Capture Pathways and Nanocarriers
Torres-Vanegas, J. D., Cruz, J. C., & Reyes, L. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030428 · Cited by 142
Platinum and Palladium Complexes as Promising Sources for Antitumor Treatments
Czarnomysy, R., Radomska, D., Szewczyk-Roszczenko, O. K., Roszczenko, P., & Bielawski, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158271 · Cited by 132
Self-Assembling Peptides: From Design to Biomedical Applications
Manna, S. L., Natale, C. D., Onesto, V., & Marasco, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312662 · Cited by 133
“Consequently, only less than 1% of the nanomaterials actually accumulate at the target site [128], being mostly phagocytized or accumulated in the liver and spleen, resulting in inefficient drug delivery [129].”
BackgroundReview: RNA-based diagnostic markers discovery and therapeutic targets development in cancer
Wang, H., Meng, Q., Qian, J., Li, M., Gu, C., & Yang, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108123 · Cited by 132
An updated review of folate-functionalized nanocarriers: A promising ligand in cancer
Ebrahimnejad, P., Sodagar Taleghani, A., Asare-Addo, K., & Nokhodchi, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.011 · Cited by 133
In Response to Precision Medicine: Current Subcellular Targeting Strategies for Cancer Therapy
Li, Z., Zou, J., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202209529 · Cited by 133
Kansız, S., & Elçin, Y. M. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.102930 · Cited by 133
Physiological principles underlying the kidney targeting of renal nanomedicines
Huang, Y., Ning, X., Ahrari, S., Cai, Q., Rajora, N., Saxena, R., Yu, M., & Zheng, J. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00819-z · Cited by 139
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Guan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0358-x · Cited by 130
Short- and Long-Term Tracking of Anionic Ultrasmall Nanoparticles in Kidney
Liang, X., Wang, H., Yi’an, Z., Zhang, R., Cogger, V. C., Liu, X., Xu, Z. P., Grice, J. E., & Roberts, M. S. (2016) · ACS Nano · doi:10.1021/acsnano.5b05066 · Cited by 132
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer
Nagesh, P. K. B., Johnson, N., Boya, V. K. N., Chowdhury, P., Othman, S. F., Khalilzad-Sharghi, V., Hafeez, B. B., Ganju, A., Khan, S., Behrman, S. W., et al. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.03.071 · Cited by 132
“In agreement with previous reports [49], SPION-Dtxl and J591-SPION-Dtxl exhibit tunable particle size in aqueous medium and in serum (< 200 nm) with negative zeta potential.”
Particle Targeting in Complex Biological Media
Dai, Q., Bertleff‐Zieschang, N., Braunger, J. A., Björnmalm, M., Cortez‐Jugo, C., & Caruso, F. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700575 · Cited by 132
Stimuli-responsive nanocarriers for delivery of bone therapeutics – Barriers and progresses
Lavrador, P., Gaspar, V. M., & Mano, J. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.021 · Cited by 129
“, Splenocytes), as well as kidney excretion (<~5 nm) (reviewed in detail in [27]).”
Biodegradable Drug-Loaded Hydroxyapatite Nanotherapeutic Agent for Targeted Drug Release in Tumors
Sun, W. C., Fan, J., Wang, S., Kang, Y., Du, J., & Peng, X. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19281 · Cited by 129
Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery
Chen, Y., Liu, X., Yuan, H., Yang, Z., Roemeling, C. A. V., Qie, Y., Hai, Z., Wang, Y., Jiang, W., & Kim, B. Y. S. (2019) · Advanced Science · doi:10.1002/advs.201802070 · Cited by 129
Zhu, J., Xiao, T., Zhang, J., Che, H., Shi, Y., Shi, X., & van Hest, J. C. M. (2020) · ACS Nano · doi:10.1021/acsnano.0c03080 · Cited by 129
Biopolymers based aerogels: A review on revolutionary solutions for smart therapeutics delivery
Khalil, H. P. S. A., Yahya, E. B., Jummaat, F. B., Adnan, A. S., Olaiya, N. G., Rizal, S., Abdullah, A. A., Pasquini, D., & Thomas, S. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.101014 · Cited by 137
mRNA nanomedicine: Design and recent applications
Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H., & Zhang, L. (2022) · Exploration · doi:10.1002/exp.20210217 · Cited by 131
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Self-citation
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
